GLP-1 Therapy Shows Promise for Glaucoma Risk Reduction

New real-world evidence suggests tirzepatide may be associated with lower glaucoma risk compared with other GLP-1 drugs in people with type 2 diabetes

In a large U.S. retrospective cohort study, patients with type 2 diabetes who used the dual GIP and GLP-1 drug tirzepatide had about half the risk of developing primary open-angle glaucoma compared with those using standard GLP-1 receptor agonists, although experts caution this finding should not change prescribing practices yet.

Study Details

Glaucoma is…